- Home
- MLKN vs ETNB Comparison
MLKN vs ETNB Comparison
Compare MLKN & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLKN
- ETNB
- Stock Information
- Founded
- MLKN 1905
- ETNB 2018
- Country
- MLKN United States
- ETNB United States
- Employees
- MLKN N/A
- ETNB N/A
- Industry
- MLKN Office Equipment/Supplies/Services
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- MLKN Consumer Discretionary
- ETNB Health Care
- Exchange
- MLKN Nasdaq
- ETNB Nasdaq
- Market Cap
- MLKN 1.5B
- ETNB 1.2B
- IPO Year
- MLKN N/A
- ETNB 2019
- Fundamental
- Price
- MLKN $19.14
- ETNB $7.34
- Analyst Decision
- MLKN
- ETNB Strong Buy
- Analyst Count
- MLKN 0
- ETNB 10
- Target Price
- MLKN N/A
- ETNB $27.56
- AVG Volume (30 Days)
- MLKN 672.7K
- ETNB 2.1M
- Earning Date
- MLKN 03-26-2025
- ETNB 05-08-2025
- Dividend Yield
- MLKN 3.80%
- ETNB N/A
- EPS Growth
- MLKN N/A
- ETNB N/A
- EPS
- MLKN 0.43
- ETNB N/A
- Revenue
- MLKN $3,597,000,000.00
- ETNB N/A
- Revenue This Year
- MLKN $4.29
- ETNB N/A
- Revenue Next Year
- MLKN $4.62
- ETNB N/A
- P/E Ratio
- MLKN $46.42
- ETNB N/A
- Revenue Growth
- MLKN N/A
- ETNB N/A
- 52 Week Low
- MLKN $17.83
- ETNB $5.99
- 52 Week High
- MLKN $31.73
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- MLKN 43.00
- ETNB 39.62
- Support Level
- MLKN $17.83
- ETNB $7.66
- Resistance Level
- MLKN $20.64
- ETNB $9.32
- Average True Range (ATR)
- MLKN 0.63
- ETNB 0.77
- MACD
- MLKN 0.12
- ETNB -0.04
- Stochastic Oscillator
- MLKN 46.62
- ETNB 9.04
About MLKN MillerKnoll Inc.
MillerKnoll Inc, formerly Herman Miller Inc researches, designs, manufactures, sells, and distributes interior furnishings across the globe. The Company has three reportable segments: Americas Contract , International Contract & Specialty International & Specialty and Global Retail. The company's products are sold through a variety of sources, including owned and independent contract furniture dealers, direct customer sales, owned and independent retailers, direct-mail catalogs, and the company's online stores. The independent retailer division generates the majority of the firm's overall sales.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).